Rede D'Or São Luiz S.A.

BOVESPA:RDOR3 Stock Report

Market Cap: R$68.6b

Rede D'Or São Luiz Valuation

Is RDOR3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RDOR3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RDOR3 (R$30.56) is trading below our estimate of fair value (R$39.71)

Significantly Below Fair Value: RDOR3 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for RDOR3?

Other financial metrics that can be useful for relative valuation.

RDOR3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.6x
Enterprise Value/EBITDA10x
PEG Ratio1.2x

Price to Earnings Ratio vs Peers

How does RDOR3's PE Ratio compare to its peers?

The above table shows the PE ratio for RDOR3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average56x
FLRY3 Fleury
13.8x13.9%R$8.3b
APOLLOHOSP Apollo Hospitals Enterprise
93.9x32.1%₹973.9b
543220 Max Healthcare Institute
85.4x27.6%₹900.4b
BDMS Bangkok Dusit Medical Services
30.7x8.2%฿468.8b
RDOR3 Rede D'Or São Luiz
21.2x18.1%R$68.6b

Price-To-Earnings vs Peers: RDOR3 is good value based on its Price-To-Earnings Ratio (21.2x) compared to the peer average (56x).


Price to Earnings Ratio vs Industry

How does RDOR3's PE Ratio compare vs other companies in the Global Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: RDOR3 is good value based on its Price-To-Earnings Ratio (21.2x) compared to the Global Healthcare industry average (22.9x).


Price to Earnings Ratio vs Fair Ratio

What is RDOR3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RDOR3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.2x
Fair PE Ratio13.8x

Price-To-Earnings vs Fair Ratio: RDOR3 is expensive based on its Price-To-Earnings Ratio (21.2x) compared to the estimated Fair Price-To-Earnings Ratio (13.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RDOR3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentR$30.56
R$39.54
+29.4%
10.7%R$45.00R$33.00n/a12
Sep ’25R$31.93
R$38.05
+19.2%
10.6%R$45.00R$33.00n/a11
Aug ’25R$28.05
R$35.39
+26.2%
8.5%R$40.00R$28.80n/a11
Jul ’25R$26.70
R$35.80
+34.1%
7.1%R$40.00R$32.00n/a10
Jun ’25R$27.46
R$34.80
+26.7%
6.9%R$40.00R$31.00n/a10
May ’25R$26.00
R$34.00
+30.8%
10.9%R$40.00R$28.00n/a11
Apr ’25R$25.28
R$34.27
+35.6%
10.0%R$40.00R$29.00n/a11
Mar ’25R$25.43
R$34.40
+35.3%
11.0%R$41.00R$29.00n/a10
Feb ’25R$26.76
R$35.30
+31.9%
10.4%R$41.00R$29.00n/a10
Jan ’25R$28.76
R$34.60
+20.3%
11.6%R$40.00R$26.00n/a10
Dec ’24R$27.14
R$35.36
+30.3%
11.7%R$41.00R$26.00n/a11
Nov ’24R$22.97
R$36.91
+60.7%
13.5%R$45.00R$26.00n/a11
Oct ’24R$25.41
R$40.00
+57.4%
11.5%R$50.00R$32.00R$30.4411
Sep ’24R$28.86
R$40.25
+39.5%
9.7%R$50.00R$35.00R$31.9312
Aug ’24R$35.51
R$39.33
+10.8%
10.1%R$50.00R$34.00R$28.0512
Jul ’24R$32.92
R$37.50
+13.9%
13.1%R$50.00R$28.00R$26.7012
Jun ’24R$30.23
R$34.33
+13.6%
15.0%R$41.00R$26.00R$27.4612
May ’24R$22.87
R$35.31
+54.4%
15.8%R$44.00R$26.00R$26.0013
Apr ’24R$21.24
R$37.54
+76.7%
11.0%R$44.00R$31.00R$25.2813
Mar ’24R$24.64
R$38.16
+54.9%
10.7%R$46.30R$31.00R$25.4314
Feb ’24R$31.90
R$38.59
+21.0%
10.3%R$46.30R$32.00R$26.7614
Jan ’24R$29.58
R$42.56
+43.9%
7.7%R$52.50R$39.00R$28.7614
Dec ’23R$30.30
R$42.70
+40.9%
7.5%R$52.50R$39.00R$27.1414
Nov ’23R$33.28
R$46.71
+40.4%
22.7%R$81.00R$39.00R$22.9714
Oct ’23R$29.72
R$49.36
+66.1%
20.8%R$81.00R$41.00R$25.4114

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies